Results 141 to 150 of about 2,325,434 (292)

Effects of SGLT2 inhibitors across the spectrum of albuminuria in cardiovascular–kidney–metabolic conditions: A pooled analysis of randomised trials

open access: yesDiabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 1105-1115, February 2026.
Abstract Background Albuminuria is associated with an increased risk of cardiovascular and kidney events. Sodium glucose co‐transporter 2 inhibitors (SGLT2i) reduce albuminuria and improve kidney outcomes in patients with albuminuric chronic kidney disease (CKD).
João Pedro Ferreira   +10 more
wiley   +1 more source

Efficacy and safety of glucagon‐like peptide 1 receptor agonists across all health outcomes in type 2 diabetes: An umbrella review and evidence map of randomised controlled trials

open access: yesDiabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 1136-1149, February 2026.
Abstract Aim Glucagon‐like peptide 1 receptor agonists (GLP‐1RAs) have been established as effective treatments for type 2 diabetes, offering benefits beyond glycaemic control; however, their associations across multiple health outcomes remain insufficiently assessed.
Dongjin Yeo   +8 more
wiley   +1 more source

Mineralocorticoid receptors in vascular function and disease

open access: yesMolecular and Cellular Endocrinology, 2012
A. Mccurley, I. Jaffe
semanticscholar   +1 more source

Emerging methods for subtype differentiation in primary aldosteronism

open access: yesJournal of Internal Medicine, Volume 299, Issue 2, Page 178-195, February 2026.
Abstract Primary aldosteronism (PA) is a common cause of hypertension. Compared to patients with essential hypertension, untreated PA is associated with a two‐ to fourfold greater risk of cardiovascular disease, renal failure, and death. PA is caused by increased secretion of aldosterone from one adrenal gland in 30% of the patients and both adrenal ...
Oskar Ragnarsson   +5 more
wiley   +1 more source

Effectiveness and safety of combining thiazides with loop diuretics vs. loop diuretics monotherapy in patients with acute decompensated heart failure: A retrospective cohort study

open access: yesBritish Journal of Clinical Pharmacology, Volume 92, Issue 1, Page 220-229, January 2026.
Aims This study investigated factors associated with and outcomes of combined loop diuretics with hydrochlorothiazide (HCTZ) for acute decompensated heart failure (ADHF). Methods In this retrospective study, adults hospitalized for ADHF and who received intravenous loop diuretics between January 2016 and March 2023 were enrolled.
Chia‐Chen Hsu   +6 more
wiley   +1 more source

Fabp5 Is the Key Regulator Mediating γ‐CEHC Differentiation in Osteoblasts and Osteoclasts

open access: yesBioFactors, Volume 52, Issue 1, January/February 2026.
γ‐CEHC, as a natural Fabp5 inhibitor, ameliorates the osteoporotic microenvironment through a triple‐action mechanism—targeting Fabp5 inhibition → modulating macrophage polarization → balancing bone metabolism—highlighting its translational medical value.
Cheng Cheng   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy